Serelaxin treatment does not reduce incidence of death in patients with AHF

http://feeds.nature.com/~r/nrcardio/rss/current/~3/LZkUZvKiYRk/s41569-019-0264-4

Nature Reviews Cardiology, Published online: 02 September 2019; doi:10.1038/s41569-019-0264-4

In patients with acute heart failure, treatment with serelaxin, a recombinant form of human relaxin 2, did not reduce the incidence of cardiovascular death or worsening heart failure.

Ryan
Ryan

No Comments

Write a Reply or Comment